As Billions in Blockbuster Drug Revenue Goes Off Patent, Life Sciences Companies are Challenged to Fundamentally Change Future R&D Strategies, According to New Deloi... (nts/subjects andbiomarkers -- Virtual...)

HOME >> BIOLOGY >> TECHNOLOGY

As Billions in Blockbuster Drug Revenue Goes Off Patent, Life Sciences Companies are Challenged to Fundamentally Change Future R&D Strategies, According to New Deloitte Report

Date:4/2/2008

nts/subjects and biomarkers

-- Virtual, disease-specific R&D networks, incorporating patients, physicians and the medical treatment infrastructure, which involves extensive partnering and collaboration with all the disease knowledge communities

-- Virtual R&D processes with significant outsourcing to maximize flexibility and manage development risk

"Leading pharmaceutical companies who follow this new R&D approach will be well positioned to reap the benefits of future R&D investments building the development pipelines required to compete in the next five years," said Dr. Cooper.

Additionally, the rise of consumerism in the health care industry further supports the urgency for change as blockbuster drugs go off patent and compete with generics. A recent Deloitte Center for Health Solutions report, 2008 Survey of Health Care Consumers (http://www.deloitte.com/us/consumerism), found that 84 percent of consumers surveyed prefer generic drugs to name brand drugs if given the choice.

"R&D investments must now more than ever be geared at developing the types of compounds that will have even greater safety and efficacy to establish branded drugs as preferred choices to contend with increasing generic competition," added Dr. Cooper.

Related Content:

Full Report: The Changing Face of R&D in the Future Pharmaceutical Landscape - http://www.deloitte.com/us/FuturePharma

Survey: 2008 Survey of Health Care Consumers - http://www.deloitte.com/us/consumerism

About Deloitte

As used in this document, "Deloitte" means Deloitte LLP. Please see http://www.deloitte.com/about for a detailed description of the legal structure of Deloitte LLP and its subsi
'/>"/>

0

GOOD

Page: 1 2 3
Related biology technology :

1. Biogenerics Will Save Billions, Says Hospira CEO
2. So Long, Old Friend: The End of the Blockbuster Drug Era? What 2008 Holds for Bringing Drugs to Market
3. Merck Will Obtain Blockbuster Antidiabetic Drug Sales in Type 2 Diabetes Market by 2011
4. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
5. Plethora and Paul Capital Healthcare sign a $25 million revenue interest financing agreement with an option for an additional $3 million equity investment
6. Kiwa Bio-Tech Year-End Revenues Increase 264% - Exceed $9.1 Million
7. Neogen Reports 34% Increase in Net Income, 20% Increase in Revenues
8. Profarmas Gross Revenue Reached R$ 740,4 Million in the 4th Quarter of 2007, a 40,1% Growth Over the Same Period in the Last Year
9. Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
10. Phlo Reports Sharp Revenue Increase
11. Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007

Post Your Comments:

As Billions in Blockbuster Drug Revenue Goes Off Patent, Life Sciences Companies are Challenged to Fundamentally Change Future R&D Strategies, According to New Deloi...(nts/subjects andbiomarkers -- Virtual...)